Samsung Biologics Signs Letter of Intent for Contract Manufacturing of Biopharmaceuticals
[Asia Economy Reporter Minji Lee] Samsung Biologics announced on the 22nd that it has signed a letter of intent for a contract to manufacture biopharmaceuticals on consignment with a Europe-based multinational pharmaceutical company. The contract amount is 48,472,480,000 KRW, which corresponds to 6.9% of the sales revenue in the most recent fiscal year.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Samsung Biologics stated, "Upon signing the main contract scheduled within the first half of the year, the contract period and the confirmed contract amount may increase."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
